Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3488)
Drug Name
LNP023
Synonyms
Iptacopan; LNP-023; UNII-8E05T07Z6W; 8E05T07Z6W; 1644670-37-0; 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid; 4-[(2~{S},4~{S})-4-ethoxy-1-[(5-methoxy-7-methyl-1~{H}-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid; Iptacopan [INN]; CHEMBL4594448; SCHEMBL16400416; GTPL10710; US9682968, Example-26a; BDBM160475; ZINC223246892; compound 41 [PMID: 32073845]; HY-127105; CS-0093107; 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid; Benzoic acid, 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-2-piperidinyl)-; JGQ
Indication IgA nephropathy [ICD11: MF8Y] Phase 3 [1]
Paroxysmal nocturnal haemoglobinuria [ICD11: ICD11: 3A20-3A2Z] Phase 3 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 422.5 Topological Polar Surface Area 74.8
Heavy Atom Count 31 Rotatable Bond Count 7
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
90467622
CAS Number
1644670-37-0
TTD Drug ID
DJ48HT
Formula
C25H30N2O4
Canonical SMILES
CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC
InChI
InChI=1S/C25H30N2O4/c1-4-31-19-10-12-27(22(14-19)17-5-7-18(8-6-17)25(28)29)15-21-20-9-11-26-24(20)16(2)13-23(21)30-3/h5-9,11,13,19,22,26H,4,10,12,14-15H2,1-3H3,(H,28,29)/t19-,22-/m0/s1
InChIKey
RENRQMCACQEWFC-UGKGYDQZSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
LNP023 Metabolite M1 DM016401
90467898
Oxidation - O-deethylation 1 [4]
LNP023 Metabolite M2 DM018968 N. A. Conjugation - Glucuronidation 1 [4] , [3]
LNP023 Metabolite M4 DM018966 N. A. Oxidation - Hydroxylation 1 [4]
LNP023 Metabolite M3 DM018967 N. A. Oxidation - Oxidation 2 [4] , [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR011359 LNP023 LNP023 Metabolite M4 Oxidation - Hydroxylation Unclear [4]
MR011361 LNP023 LNP023 Metabolite M2 Conjugation - Glucuronidation UGT1A1 [4], [3]
MR011362 LNP023 LNP023 Metabolite M1 Oxidation - O-deethylation Unclear [4]
MR011360 LNP023 Metabolite M4 LNP023 Metabolite M3 Oxidation - Oxidation CYP2C8 [4], [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[3]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME0004 Homo sapiens
UD11_HUMAN
2.4.1.17
[3]
References
1 ClinicalTrials.gov (NCT04578834) Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04558918) Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment (APPLY-PNH). U.S. National Institutes of Health.
3 Absorption, Distribution, Metabolism, and Excretion of [(14)C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies
4 Pharmacokinetics and metabolism of LNP023 in rats by liquid chromatography combined with electrospray ionization-tandem mass spectrometry

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.